CPVTNext®
Use
CPVTNext is a multi-gene panel designed to identify individuals at risk for catecholaminergic polymorphic ventricular tachycardia (CPVT), a hereditary cardiovascular disorder. It is especially useful as CPVT can often be asymptomatic, with sudden death being the first symptom. Genetic testing supports the diagnosis and management of patients by identifying pathogenic mutations that are common in CPVT cases.
Special Instructions
Family variant testing is offered at no additional cost for all blood relatives of patients with identified pathogenic variants, within 90 days of the original report date. Testing is applicable for patients receiving medical care in the U.S. or US territories. Family testing should prioritize close relatives.
Limitations
The CPVTNext test is capable of detecting more than 99% of mutations in the genes covered by the panel. However, clinical sensitivity may vary widely based on individual and family clinical history. Exon-level resolution may be limited for certain genes due to technical constraints, and it may not detect all possible genetic variants, such as those outside of targeted regions or at low allele frequencies.
Methodology
NGS
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided